世界のアテローム性動脈硬化症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Atherosclerosis Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5602 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、アテローム性動脈硬化症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（小分子、生物製剤）、用途別市場規模（病院、診療所、研究機関、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・アテローム性動脈硬化症治療薬の市場動向 ・企業の競争状況、市場シェア ・アテローム性動脈硬化症治療薬の種類別市場規模と予測2016-2027（小分子、生物製剤） ・アテローム性動脈硬化症治療薬の用途別市場規模と予測2016-2027（病院、診療所、研究機関、その他） ・アテローム性動脈硬化症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・アテローム性動脈硬化症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・アテローム性動脈硬化症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・アテローム性動脈硬化症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・アテローム性動脈硬化症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca Plc、Bayer AG、Merck & Co. Inc.、Novartis AG、Sanofi） ・結論

Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.
The identification of new drug targets for atherosclerosis will be one of the critical atherosclerosis therapeutics market trends driving the growth of the market. Although statins are regarded as the first line of treatment for decreasing LDL levels in the body, it exhibits secondary effects, such as hepatic enzyme elevation or muscular pain in some patients. Moreover, statins do not decrease the risk of cardiovascular diseases completely and is not recommended for patients having diabetes. This has encouraged researchers to focus on the evaluation of new drug targets, including triglyceride-rich particle metabolism regulators, proteins involved in glycoprotein recognition and clearance, and inflammatory pathways that affect efferocytosis. For instance, new proatherosclerotic pathways, such as lipoprotein A (LPA) and PCSK9 can significantly minimize the risk of atherosclerosis. PCSK9 inhibitors exhibit high therapeutic efficacy in reducing atherogenesis and do not increase the incidence of type 2 diabetes. Although more clinical trials are required for their use among atherosclerosis patients, continuous R&D in this field will positively impact the growth of the atherosclerosis therapeutics market.

Market Analysis and Insights: Global Atherosclerosis Therapeutics Market
The global Atherosclerosis Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Atherosclerosis Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Atherosclerosis Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Atherosclerosis Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Atherosclerosis Therapeutics market.

Global Atherosclerosis Therapeutics Scope and Market Size
Atherosclerosis Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Atherosclerosis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Small Molecules
Biologics

Segment by Application
Hospital
Clinic
Research Institute
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca Plc
Bayer AG
Merck & Co. Inc.
Novartis AG
Sanofi

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Atherosclerosis Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Small Molecules
1.2.3 Biologics
1.3 Market by Application
1.3.1 Global Atherosclerosis Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Atherosclerosis Therapeutics Market Perspective (2016-2027)
2.2 Atherosclerosis Therapeutics Growth Trends by Regions
2.2.1 Atherosclerosis Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Atherosclerosis Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Atherosclerosis Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Atherosclerosis Therapeutics Industry Dynamic
2.3.1 Atherosclerosis Therapeutics Market Trends
2.3.2 Atherosclerosis Therapeutics Market Drivers
2.3.3 Atherosclerosis Therapeutics Market Challenges
2.3.4 Atherosclerosis Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Atherosclerosis Therapeutics Players by Revenue
3.1.1 Global Top Atherosclerosis Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Atherosclerosis Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Atherosclerosis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Atherosclerosis Therapeutics Revenue
3.4 Global Atherosclerosis Therapeutics Market Concentration Ratio
3.4.1 Global Atherosclerosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Atherosclerosis Therapeutics Revenue in 2020
3.5 Atherosclerosis Therapeutics Key Players Head office and Area Served
3.6 Key Players Atherosclerosis Therapeutics Product Solution and Service
3.7 Date of Enter into Atherosclerosis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Atherosclerosis Therapeutics Breakdown Data by Type
4.1 Global Atherosclerosis Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Atherosclerosis Therapeutics Forecasted Market Size by Type (2022-2027)

5 Atherosclerosis Therapeutics Breakdown Data by Application
5.1 Global Atherosclerosis Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Atherosclerosis Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Atherosclerosis Therapeutics Market Size (2016-2027)
6.2 North America Atherosclerosis Therapeutics Market Size by Type
6.2.1 North America Atherosclerosis Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Atherosclerosis Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Atherosclerosis Therapeutics Market Size by Type (2016-2027)
6.3 North America Atherosclerosis Therapeutics Market Size by Application
6.3.1 North America Atherosclerosis Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Atherosclerosis Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Atherosclerosis Therapeutics Market Size by Application (2016-2027)
6.4 North America Atherosclerosis Therapeutics Market Size by Country
6.4.1 North America Atherosclerosis Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Atherosclerosis Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Atherosclerosis Therapeutics Market Size (2016-2027)
7.2 Europe Atherosclerosis Therapeutics Market Size by Type
7.2.1 Europe Atherosclerosis Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Atherosclerosis Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Atherosclerosis Therapeutics Market Size by Type (2016-2027)
7.3 Europe Atherosclerosis Therapeutics Market Size by Application
7.3.1 Europe Atherosclerosis Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Atherosclerosis Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Atherosclerosis Therapeutics Market Size by Application (2016-2027)
7.4 Europe Atherosclerosis Therapeutics Market Size by Country
7.4.1 Europe Atherosclerosis Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Atherosclerosis Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Atherosclerosis Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Atherosclerosis Therapeutics Market Size by Type
8.2.1 Asia-Pacific Atherosclerosis Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Atherosclerosis Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Atherosclerosis Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Atherosclerosis Therapeutics Market Size by Application
8.3.1 Asia-Pacific Atherosclerosis Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Atherosclerosis Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Atherosclerosis Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Atherosclerosis Therapeutics Market Size by Region
8.4.1 Asia-Pacific Atherosclerosis Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Atherosclerosis Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Atherosclerosis Therapeutics Market Size (2016-2027)
9.2 Latin America Atherosclerosis Therapeutics Market Size by Type
9.2.1 Latin America Atherosclerosis Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Atherosclerosis Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Atherosclerosis Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Atherosclerosis Therapeutics Market Size by Application
9.3.1 Latin America Atherosclerosis Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Atherosclerosis Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Atherosclerosis Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Atherosclerosis Therapeutics Market Size by Country
9.4.1 Latin America Atherosclerosis Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Atherosclerosis Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Atherosclerosis Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Atherosclerosis Therapeutics Market Size by Type
10.2.1 Middle East & Africa Atherosclerosis Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Atherosclerosis Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Atherosclerosis Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Atherosclerosis Therapeutics Market Size by Application
10.3.1 Middle East & Africa Atherosclerosis Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Atherosclerosis Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Atherosclerosis Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Atherosclerosis Therapeutics Market Size by Country
10.4.1 Middle East & Africa Atherosclerosis Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Atherosclerosis Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Company Details
11.1.2 AstraZeneca Plc Business Overview
11.1.3 AstraZeneca Plc Atherosclerosis Therapeutics Introduction
11.1.4 AstraZeneca Plc Revenue in Atherosclerosis Therapeutics Business (2016-2021)
11.1.5 AstraZeneca Plc Recent Development
11.2 Bayer AG
11.2.1 Bayer AG Company Details
11.2.2 Bayer AG Business Overview
11.2.3 Bayer AG Atherosclerosis Therapeutics Introduction
11.2.4 Bayer AG Revenue in Atherosclerosis Therapeutics Business (2016-2021)
11.2.5 Bayer AG Recent Development
11.3 Merck & Co. Inc.
11.3.1 Merck & Co. Inc. Company Details
11.3.2 Merck & Co. Inc. Business Overview
11.3.3 Merck & Co. Inc. Atherosclerosis Therapeutics Introduction
11.3.4 Merck & Co. Inc. Revenue in Atherosclerosis Therapeutics Business (2016-2021)
11.3.5 Merck & Co. Inc. Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Atherosclerosis Therapeutics Introduction
11.4.4 Novartis AG Revenue in Atherosclerosis Therapeutics Business (2016-2021)
11.4.5 Novartis AG Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Atherosclerosis Therapeutics Introduction
11.5.4 Sanofi Revenue in Atherosclerosis Therapeutics Business (2016-2021)
11.5.5 Sanofi Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Atherosclerosis Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Small Molecules
Table 3. Key Players of Biologics
Table 4. Global Atherosclerosis Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Atherosclerosis Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Atherosclerosis Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Atherosclerosis Therapeutics Market Share by Regions (2016-2021)
Table 8. Global Atherosclerosis Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Atherosclerosis Therapeutics Market Share by Regions (2022-2027)
Table 10. Atherosclerosis Therapeutics Market Trends
Table 11. Atherosclerosis Therapeutics Market Drivers
Table 12. Atherosclerosis Therapeutics Market Challenges
Table 13. Atherosclerosis Therapeutics Market Restraints
Table 14. Global Atherosclerosis Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Atherosclerosis Therapeutics Market Share by Players (2016-2021)
Table 16. Global Top Atherosclerosis Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Atherosclerosis Therapeutics as of 2020)
Table 17. Ranking of Global Top Atherosclerosis Therapeutics Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Atherosclerosis Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Atherosclerosis Therapeutics Product Solution and Service
Table 21. Date of Enter into Atherosclerosis Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Atherosclerosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Atherosclerosis Therapeutics Revenue Market Share by Type (2016-2021)
Table 25. Global Atherosclerosis Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Atherosclerosis Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Atherosclerosis Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Atherosclerosis Therapeutics Revenue Market Share by Application (2016-2021)
Table 29. Global Atherosclerosis Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Atherosclerosis Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Atherosclerosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Atherosclerosis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Atherosclerosis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Atherosclerosis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Atherosclerosis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Atherosclerosis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Atherosclerosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Atherosclerosis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Atherosclerosis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Atherosclerosis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Atherosclerosis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Atherosclerosis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Atherosclerosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Atherosclerosis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Atherosclerosis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Atherosclerosis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Atherosclerosis Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Atherosclerosis Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Atherosclerosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Atherosclerosis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Atherosclerosis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Atherosclerosis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Atherosclerosis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Atherosclerosis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Atherosclerosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Atherosclerosis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Atherosclerosis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Atherosclerosis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Atherosclerosis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Atherosclerosis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 61. AstraZeneca Plc Company Details
Table 62. AstraZeneca Plc Business Overview
Table 63. AstraZeneca Plc Atherosclerosis Therapeutics Product
Table 64. AstraZeneca Plc Revenue in Atherosclerosis Therapeutics Business (2016-2021) & (US$ Million)
Table 65. AstraZeneca Plc Recent Development
Table 66. Bayer AG Company Details
Table 67. Bayer AG Business Overview
Table 68. Bayer AG Atherosclerosis Therapeutics Product
Table 69. Bayer AG Revenue in Atherosclerosis Therapeutics Business (2016-2021) & (US$ Million)
Table 70. Bayer AG Recent Development
Table 71. Merck & Co. Inc. Company Details
Table 72. Merck & Co. Inc. Business Overview
Table 73. Merck & Co. Inc. Atherosclerosis Therapeutics Product
Table 74. Merck & Co. Inc. Revenue in Atherosclerosis Therapeutics Business (2016-2021) & (US$ Million)
Table 75. Merck & Co. Inc. Recent Development
Table 76. Novartis AG Company Details
Table 77. Novartis AG Business Overview
Table 78. Novartis AG Atherosclerosis Therapeutics Product
Table 79. Novartis AG Revenue in Atherosclerosis Therapeutics Business (2016-2021) & (US$ Million)
Table 80. Novartis AG Recent Development
Table 81. Sanofi Company Details
Table 82. Sanofi Business Overview
Table 83. Sanofi Atherosclerosis Therapeutics Product
Table 84. Sanofi Revenue in Atherosclerosis Therapeutics Business (2016-2021) & (US$ Million)
Table 85. Sanofi Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Atherosclerosis Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Small Molecules Features
Figure 3. Biologics Features
Figure 4. Global Atherosclerosis Therapeutics Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Research Institute Case Studies
Figure 8. Other Case Studies
Figure 9. Atherosclerosis Therapeutics Report Years Considered
Figure 10. Global Atherosclerosis Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Atherosclerosis Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Atherosclerosis Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Atherosclerosis Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Atherosclerosis Therapeutics Market Share by Players in 2020
Figure 15. Global Top Atherosclerosis Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Atherosclerosis Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Atherosclerosis Therapeutics Revenue in 2020
Figure 17. Global Atherosclerosis Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Atherosclerosis Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Atherosclerosis Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Atherosclerosis Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Atherosclerosis Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Atherosclerosis Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Atherosclerosis Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Atherosclerosis Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Atherosclerosis Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Atherosclerosis Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Atherosclerosis Therapeutics Market Share by Region (2016-2027)
Figure 39. China Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Atherosclerosis Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Atherosclerosis Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Atherosclerosis Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Atherosclerosis Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Atherosclerosis Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Atherosclerosis Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Atherosclerosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. AstraZeneca Plc Revenue Growth Rate in Atherosclerosis Therapeutics Business (2016-2021)
Figure 59. Bayer AG Revenue Growth Rate in Atherosclerosis Therapeutics Business (2016-2021)
Figure 60. Merck & Co. Inc. Revenue Growth Rate in Atherosclerosis Therapeutics Business (2016-2021)
Figure 61. Novartis AG Revenue Growth Rate in Atherosclerosis Therapeutics Business (2016-2021)
Figure 62. Sanofi Revenue Growth Rate in Atherosclerosis Therapeutics Business (2016-2021)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

---